Novartis strikes up to $7.8 billion mRNA deal with China's Abogen

2

By Bhanvi Satija Oct 2 (Reuters) – Chinese biotech company Abogen said on Friday it has signed a licensing deal worth up to $7.8 billion with Novartis to develop messenger RNA-based therapies,

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)